(Q53220254)

English

Optimising the lymphoma response criteria in the era of targeted therapy.

scientific article published on 12 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

Optimising the lymphoma response criteria in the era of targeted therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

author name string

Anas Younes

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

Anton Hagenbeek

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

Bertrand Coiffier

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

publication date

12 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

12

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

616-617

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

Beyond chemotherapy: new agents for targeted treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970132-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970132-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970132-2

7 January 2021

based on heuristic

inferred from DOI database lookup

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970132-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70132-2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21659000

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53220254&oldid=1417658698"